Viscient Biosciences

About:

Viscient Biosciences is a biotechnology company working at the intersection of human 3D tissue technology and multi-omics analysis.

Website: http://www.viscientbiosciences.com

Top Investors: SternAegis, Harmonix Fund, Thynk Capital

Description:

Viscient Biosciences is a biotechnology company working at the intersection of human 3D tissue technology and multi-omics (genomics, transcriptomics, metabolomics) analysis to develop drugs across a range of therapeutic areas, with an initial focus in non-alcoholic steatohepatitis (NASH,“fatty liver disease”). Founded and staffed by a team composed of former Organovo and Ardea Biosciences scientists and entrepreneurs, Viscient is driving a revolution in drug discovery, overthrowing the old paradigm of discovery in animal models.

Total Funding Amount:

$5.73M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

San Diego, California, United States

Founded Date:

2017-12-01

Contact Email:

info(AT)viscientbio.com

Founders:

Jeffrey Miner, Keith Murphy

Number of Employees:

11-50

Last Funding Date:

2021-09-15

IPO Status:

Private

Industries:

© 2025 bioDAO.ai